US FDA rejects Eisai/Astex drug for AML indication
This article was originally published in Scrip
Executive Summary
Investors obviously had been preparing themselves for a rejection from the US FDA for Eisai's and Astex Pharmaceuticals' nucleoside metabolic inhibitor Dacogen (decitabine) as a treatment for acute myeloid leukaemia (AML) in older adults, with shares of the latter company first falling 3.8% in morning trading on 7 March, before the stock regained its composure, even getting a bump of 2.7%, or 5 cents.